Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colonic Neoplasms 66Rectal Neoplasms 61Colorectal Neoplasms 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasm Metastasis 12Lymphoma 12Burkitt Lymphoma 11Leukemia 9Unspecified Adult Solid Tumor, Protocol Specific 7Lymphoma, Non-Hodgkin 6Leukemia, Biphenotypic, Acute 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Pancreatic Neoplasms 5Gallbladder Neoplasms 5Bile Duct Neoplasms 5Acquired Immunodeficiency Syndrome 5Neoplasms 4HIV Infections 4Osteosarcoma 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Neoplasms, Unknown Primary 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Cutaneous 2

Interventions

Oxaliplatin 2glucarpidase 1Vincristine 1Pharmacogenomic Testing 1Leucovorin 1Gene Expression Profiling 1Folfox protocol 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neurotoxicity Syndromes × Leucovorin × Clear all
NCT00884767 2009-07-08

Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

National Cancer Institute (NCI)

Phase 2 Unknown
206 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡